comprehensive -WSS

comprehensive

author：focus 2025-08-25 07:27:15 - browse：9

Eli Lilly said Friday it will acquire Versanis Bio, a private company developing an obesity drug that specifically targets fat mass, as the race among pharmaceutical companies to offer weight loss medications intensifies.

The deal indicates Lilly is aiming to diversify its growing portfolio of weight loss therapies, as Versanis’ drug employs an entirely different mechanism than the existing obesity drugs that Lilly is studying. The pharma giant didn’t say how much it would pay Versanis upfront, but said that if the drug meets certain milestones, the total payment could reach $1.9 billion.

Lilly, along with other pharma companies like Novo Nordisk, has been developing products in the class of GLP-1 drugs, which mimic the glucagon-like peptide 1 hormone that helps people feel full. These drugs – including Novo’s Ozempic and Wegovy, and Lilly’s Mounjaro – have exploded in popularity because they lead to significant weight loss.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： New air purifier tech could be key to improving indoor air quality
Next article： MassMutual is introducing free genetic testing for members

hotspot

WSS

MassMutual is introducing free genetic testing for members

Life science postdocs should get big pay hike, NIH panel says

Medicare Advantage coverage denials need scrutiny, senators say

BIO: Crackdown on China pharma industry would threaten U.S. drug supply

MassMutual is introducing free genetic testing for members

Melinda French Gates resigns from Gates Foundation

entertainment

comprehensive

hotspot

At least 13 dead in Texas as scorching temps continue

Profiling embryos to choose those with higher IQs is almost a reality

In Memoriam: Notable people who died in 2023

Medicare Advantage overpayments discussion gets experts fired up

Affirmative action in medical school literally saved lives

Dogs on Prozac: What pet anti

After affirmative action ruling, medical educators look to 'holistic review'

Physician assistants need a new name. Here's what it should be

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Readout Newsletter: Novavax stock, FogPharma, Novo Nordisk

focus

Ascension's ugly legal battle over care for poor patients in Texas

STAT Virtual Event: JPM Recap, Live!

Readout Newsletter: Cytokinetics and Novartis' starcrossed tale

Readout Newsletter: Cytokinetics and Novartis' starcrossed tale

Melinda French Gates resigns from Gates Foundation

Profiling embryos to choose those with higher IQs is almost a reality

Wikipedia

focus

hotspot

hotspot